Abstract:BACKGROUND:Neoadjuvant chemotherapy has become standard treatment for women with locally advanced breast cancer. The aim of this study was to compare the efficacy and safety of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) versus paclitaxel combined with carboplatin. METHODS:Thirty patients were treated with neoadjuvant nab-paclitaxel (125 mg/m(2), days 1, 8, and 15) and carboplatin (area under the curve =2; days 1, 8, and 15) every 21 days for four cycles. Ninety matched patients received paclitaxel (80 mg/m(2), days 1, 8, and 15) and carboplatin every 21 days for four cycles. Weekly trastuzumab is recommended for overexpression of human epidermal receptor-2. The primary endpoint was pathologic complete response (defined as ypT0/is ypN0). Matching was conducted according to six variables: body mass index, clinical tumor stage, clinical lymph node status, estrogen receptor status, HER2 status, and trastuzumab receiving rate. RESULTS:Ninety percent of patients in the nab-paclitaxel group and 80% of patients in the paclitaxel group experienced a clinical objective response (complete response or partial response; P=0.450). Eight patients in the nab-paclitaxel group and 23 patients in the paclitaxel group had a pathologic complete response in the breast and axillary nodes (26.7% versus 25.6%; P=0.904). Nab-paclitaxel showed a beneficial effective trend on clinical tumor stage II (36.8% versus 15.8%; P=0.051). When trastuzumab was added to nab-paclitaxel, the pathologic complete response rate was not significantly improved more than with trastuzumab and paclitaxel (43.6% versus 39.6%; P=0.769). Carboplatin plus nab-paclitaxel or paclitaxel had similarly low pathologic complete response rates (7.7% versus 10.5%) for the luminal molecular subtype. One (50%) triple-negative patient achieved a pathologic complete response. The nab-paclitaxel regimen caused more grade 4 neutropenia than the paclitaxel regimen (56.7% versus 21.1%; P<0.001). CONCLUSION:Our study shows that weekly nab-paclitaxel and carboplatin with or without trastuzumab resulted in a pathologic complete response rate that was not superior to the matched cohorts. Future, larger trials are needed to validate that nab-paclitaxel is beneficial for clinical tumor stage II and the triple-negative subgroup.

Efficacy and Safety of Weekly Intravenous Nanoparticle Albumin-Bound Paclitaxel for Non-Small Cell Lung Cancer Patients Who Have Failed at Least Two Prior Systemic Treatments

A Retrospective Study in Chinese Patients: is There a Role of Nanoparticle Albumin Bound Paclitaxel in Advanced NSCLC?

Weekly Albumin-Bound Paclitaxel/cisplatin Versus Gemcitabine/cisplatin As First-Line Therapy for Patients with Advanced Non-Small-cell Lung Cancer: A Phase II Open-Label Clinical Study

A Phase Ii Study of Weekly Nanoparticle Albumin-Bound Paclitaxel Combined with Cisplatin in Patients with Metastatic Breast Cancer

Assessing the Clinical Outcome of Nab-Paclitaxel in Chinese Patients with Advanced Non-Small-cell Lung Cancer.

Weekly albumin-bound paclitaxel/cisplatin versus gemcitabine/cisplatin as first-line therapy for patients with advanced non-small-cell lung cancer: A phase II open-label clinical study.

Outcome of Advanced Nonsmall Cell Lung Cancer Patients Receiving Gemcitabine and Weekly Paclitaxel As First-Line Treatment

A multicentre randomised trial comparing weekly paclitaxel + S-1 with weekly paclitaxel + 5-fluorouracil for patients with advanced gastric cancer.

[A Phase II Prospective Randomized Controlled Trial of Weekly Paclitaxel Combined with S-1 or Fluorouracil for Advanced Gastric Carcinoma].

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Paclitaxel-Carboplatin Alone or with Endostar for Advanced Non-small Cell Lung Cancer

Safety Analysis of Weekly Paclitaxel Plus S-1 Versus Paclitaxel Plus 5-Fluorouracil/calcium Folinate As First-Line Therapy in Advanced Gastric Cancer: a Multicenter Open Random Phase II Trial

Efficacy and safety of nanoparticle albumin‐bound paclitaxel in taxane‐pretreated metastatic breast cancer patients

Efficacy and safety of nanoparticle albumin‐bound paclitaxel monotherapy after immune checkpoint inhibitor administration for advanced non‐small cell lung cancer: A multicenter Phase 2 clinical trial

A Study of Weekly Docetaxel and Carboplatin As First-Line Chemotherapy for Advanced Non-Small Cell Lung Cancer.

A Phase II Study of Weekly Nab-Paclitaxel in Combination with Gemcitabine in Patients with Metastatic Breast Cancer.

A Phase Ii Study of Biweekly Oxaliplatin and S-1(Sox) As First-Line Combination Therapy in Patients with Advanced Gastric Cancer.

Nanoparticle albumin bound-paclitaxel for treatment of advanced non-small cell lung cancer: an evaluation of the clinical evidence

A Phase II Trial of Weekly Paclitaxel and High-Dose 5-Fluorouracil Plus Leucovorin in Patients with Chemotherapy-Pretreated Metastatic Breast Cancer.

Efficacy of weekly paclitaxel-bevacizumab combination in advanced non squamous non-small cell lung cancer (NSCLC): A retrospective multicentric study

The efficacy and safety of nanoparticle albumin bound‐paclitaxel‐based regimen as second‐ or third‐line treatment in patients with advanced esophageal squamous cell carcinoma

Phase II trial of weekly nab-paclitaxel and carboplatin treatment with or without trastuzumab as nonanthracycline neoadjuvant chemotherapy for locally advanced breast cancer.